Adult Vaccines Market Headed for Growth and Global Expansion by 2026 Adult Vaccines Market - by Vaccine (Influenza, Tetanus/Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis, and Others), by Vaccine Type (Monovalent and Multivalent), by Technology (Live Attenuated Vaccines, Inactivated Viral or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Conjugate Vaccines), and by Region - Global Industry Insights, and Forecast till 2025 The Global Adult Vaccines Market was valued at US$ 12,806.49 million in 2017 and is expected to witness a robust CAGR of 7.1% over the forecast period (2017 – 2025). Vaccination and immunization is aids in prevention of diseases among adults and children. Vaccines are biological suspensions that contain an agent that resembles the disease causing microorganisms and are often made from inactivated microbes, toxins or surface proteins. The active agents present in the vaccine stimulates body’s immune system to recognize the disease causing agent as 'foreign substance' and develop antibodies against it. Vaccines are a preferable and highly recommended preventive measure against certain severe diseases, however, have mild side effects. Market Dynamics Development of vaccines for various new diseases and rising awareness regarding advantages of preventive medication are the two prominent factors supporting growth of the market. For instance, according to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden. Factors such as increasing number of government initiatives to prevent certain diseases and epidemic caused due to vaccine-preventable diseases. Additionally, increasing number of countries are conducting national immunization programs to provide vaccination and promote awareness regarding advantages of vaccination to fight fatal diseases with natural immunity among adults as well as children. For instance, in 2015, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) partnered with the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to support the advanced development of new and better influenza vaccines, as a part of inter-agency government effort in the U.S. Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1091 Market players are engaged in development vaccines to cater to diseases with high epidemic Market players are increasingly focusing on developing vaccines that caters to diseases with highest probability of causing an epidemic. For instance, in February 2017, an India-based drug firm, Cipla, in collaboration with Serum Institute of India, introduced Hepatitis B vaccine for adults in the country. The disease affects chronically over 40 million people in the country, as per India’s Universal Immunization Programme. Moreover, Dynavax Technologies Corporation received FDA approval in 2018, for its two-dosed Hepatitis-B vaccine indicated for adults aged 18 years and older. Key players operating in the global adult vaccines market include GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer, Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc. Detailed Segmentation: •Global Adult Vaccines Market, By Vaccine: •Influenza •Tetanus, Diphtheria, Pertussis (Td/Tdap) •Varicella •Human Papillomavirus •Zoster •Measles, Mumps, Rubella (MMR) •Pneumococcal •Hepatitis •Others •Global Adult Vaccines Market, By Vaccine Type: •Monovalent •Multivalent •Global Adult Vaccines Market, By Technology: •Live Attenuated Vaccines •Inactivated Viral/Bacterial Vaccines •Toxoid Vaccines •Recombinant Vaccines •Conjugate Vaccines On the other hand, growing awareness among the populace regarding prevention of diseases facilitated by vaccines is expected to augment the market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden. Moreover, according to a study from the Society for Risk Analysis, 2016, GDP loss of a pandemic outbreak in the U.S. was recorded between US$ 34.4 billion and US$ 45.3 billion. However, a large population not being vaccinated poses as a restraint for growth of the market. Moreover, favorable Medicare coverage for adult vaccination in the U.S. also poses as a key factor favoring growth of the adult vaccines market. For instance, National Health Interview Survey (NHIS), 2015, reports an increase of 2.8% increased risk for pneumococcal disease among adults aged 19-64 years. The market in Asia Pacific is expected to witness significant traction, owing to extensive research conducted by the local players to cater to the increasing prevalence of diseases for which vaccines have not been developed. Demand still high in the Developed Markets Geographically, the hospice & palliative care centers market is segmented into North America, Europe, Asia Pacific, Latin America and Rest of the World. Hospice and palliative care centers are now recognized as a medical subspecialty by the American Board of Medical Specialties, as well as in Australia, Canada, England, New Zealand, and Ireland. Many European countries are also in the process of developing certification for palliative care. Most private health insurance companies include hospice care as a benefit. Some hospices are able to provide services without charge if a patient has limited or no financial resources. Hospice care expenses in U.S. are mostly paid by the Medicare and Medicaid services and the Department of Veterans Affairs. About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1–206–701–6702 Email: [email protected]

The Global Adult Vaccines Market was valued at US$ 12,806.49 million in 2017 and is expected to witness a robust CAGR of 7.1% over the forecast period (2017 – 2025). Vaccination and immunization is aids in prevention of diseases among adults and children.